Phase II Study of Intravenous Menogaril in Patients With Advanced Breast Cancer
- 7 September 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 80 (13) , 1066-1069
- https://doi.org/10.1093/jnci/80.13.1066
Abstract
Menogaril was administered to 40 patients with advanced breast cancer who had not received anthracy-cline drugs previously. The drug was given iv as a 2-hour infusion, repeated every 4 weeks, at doses of 200 mg/m2 and 160 mg/m2 in good-risk and poor-risk patients. The overall response rate was 22% in patients with no prior chemotherapy and 10% in patients previously exposed to chemotherapy. Leukopenia was generally moderate and predictable. Phlebitis and erythema along the vein injected occurred in 34% and 17% of the cases, respectively. Menogaril is an active drug used in the treatment of patients with advanced breast cancer who have not had prior systemic therapy. [J Natl Cancer Inst 1988;80:1066–1069]This publication has 6 references indexed in Scilit:
- PHASE-I STUDY AND PHARMACOKINETICS OF MENOGARIL (NSC 269148) IN PATIENTS WITH HEPATIC-DYSFUNCTION1987
- Phase I study of intravenous menogaril administered intermittently.Journal of Clinical Oncology, 1986
- BISANTRENE, AN ACTIVE NEW DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER1983
- INTRACELLULAR UPTAKE OF 7-CON-O-METHYLNOGAROL AND ADRIAMYCIN BY CELLS IN CULTURE AND ITS RELATIONSHIP TO CELL-SURVIVAL1981
- CHRONIC CARDIOTOXICITY STUDIES IN RABBITS WITH 7-CON-0-METHYLNOGAROL, A NEW ANTHRACYCLINE ANTI-TUMOR AGENT1979
- Perspectives in the Treatment of Breast Cancer: 1976Annals of Internal Medicine, 1977